An estimated 25 percent of globally manufactured drugs contain highly potent active pharmaceutical ingredients (HPAPIs). HPAPI drugs, which include small-molecule and biologic compounds as well as antibodydrug conjugates (ADCs), are often used in the treatment of cancer. The fastest growing segment of the HPAPI market are ADCs, a new class of therapeutic agents that deliver cytotoxic drugs selectively to antigen-expressing tumor cells. Non-oncology HPAPI compounds include hormones, narcotics, and retinoids.
Because HPAPI compounds are more selective and require relatively small dosages, they offer many therapeutic advantages over their lower potency counterparts. As a result, the global market for HPAPI drugs is expected to grow by an estimated compound annual growth rate of 9.9 percent in the next three years (2015-2018).